NYZ Stock Chart & Stats
€0.47
>-€0.01(-0.67%)
At close: 4:00 PM EDT
€0.47
>-€0.01(-0.67%)
Day’s Range― - ―
52-Week Range€0.29 - €0.97
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€34.91M
Enterprise Value€17.64
Total Cash (Recent Filing)€19.14M
Total Debt (Recent Filing)€10.44M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding72,588,090
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)1.35
P/FCF Ratio-3.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€30.37M
Bulls Say, Bears Say
Bulls Say
IVDR Regulatory PositionIVDR accreditation strengthens Novacyt’s ability to commercialize compliant diagnostic products in Europe and may raise barriers for less-prepared competitors. Management expects this positioning to reduce competitor activity over the next 12–24 months, supporting longer-term market access and differentiation.
Strong Gross MarginThe 63% blended gross margin, supported by PCR and RUO products with margins above 80%, indicates meaningful product economics. If maintained as revenue scales, this gives Novacyt scope to absorb operating costs, fund development, and improve profitability without relying solely on price increases.
Clinical Franchise And NIPT GrowthA clinical business representing most group revenue provides a substantial foundation beyond short-lived outbreak testing. NIPT growth, new hospital contracts, and double-digit Asia-Pacific expansion suggest increasing adoption and geographic diversification that can support recurring diagnostic demand over the next several quarters.
Bears Say
Persistent UnprofitabilityNovacyt has not yet demonstrated a sustainably profitable operating model: losses persisted across five years and FY2025 still included a sizeable EBITDA deficit. Continued unprofitability limits internally funded growth and means the company must execute its revenue and cost-control plans before earnings become durable.
Ongoing Cash ConsumptionNegative operating and free cash flow show that reported revenue and gross profit have not yet translated into self-funded operations. The decline in cash to GBP 11m increases financing sensitivity and leaves less flexibility to absorb execution setbacks, fund development, or meet obligations while losses continue.
SMA Regulatory DelayThe SMA setback delays a product launch and creates uncertainty over the eventual development route, approval timing, and profitability. This weakens the near-term contribution from the pipeline and adds execution risk at a company that is relying on new products and growth initiatives to reach EBITDA profitability.
Novacyt News
NYZ FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.29 and its highest was €0.97 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €34.91M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Sep 24, 2026 which is in 5 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Apr 30, 2026. The company reported -€0.269 earnings per share for the quarter.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -€0.269 in its last earnings report. Following the earnings report the stock price went down -15.819%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in DE:NYZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
NYZ Company Deck
NYZ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.View all DE:NYZ earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―